Dogmas and Controversies in Hematologic Malignancies: Los Angeles

Redondo Beach, CA US
March 28, 2025 to March 29, 2025

Dogmas and Controversies in Hematologic Malignancies: Los Angeles is an annual 2-day CME-accredited conference featuring leading experts who will deliver a comprehensive review of current and emerging strategies for managing Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic leukemia, acute leukemias, myeloproliferative neoplasms, and multiple myeloma.

This program aims to enhance participants’ knowledge and competence in applying practice-changing clinical data and expert recommendations to optimize outcomes for patients with hematologic malignancies. Through scientific debates, panel discussions, and in-depth analysis, the conference will address key controversies and advances in the field, with a focus on integrating innovative therapies into clinical practice. Designed for a multidisciplinary audience of physicians, advanced practice providers, pharmacists, nurses, and other healthcare professionals, the conference emphasizes evidence-based approaches and a patient-centered care model. Participants will gain actionable insights to improve clinical outcomes and stay informed on the latest developments in hematologic malignancies.

Target Audience

  • Cancer care professionals
  • Medical Oncologists and Hematologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

Organizing Committee 

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs: 

Alexey V. Danilov, MD, PhD - City of Hope Medical Center

Thomas G. Martin, MD - UCSF Helen Diller Family Comprehensive Cancer Center

Vinod Pullarkat, MD, MRCP - City of Hope Medical Center

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

GLOBAL ONCOLOGY PROJECT

To learn more about our ongoing project building a 200-bed cancer hospital in Nepal.

Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-006-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
10/08/2024
Course expires: 
07/25/2025
Event starts: 
03/28/2025 - 1:30pm PDT
Event ends: 
03/29/2025 - 5:30pm PDT
Cost:
$350.00
Add to calendar: 

DAY 1 - Friday, March 28th, 2025

All times listed in Pacific Time Zone (PT)
 

12:30 PM – 01:30 PM  Registration, Networking, & Exhibits

01:30 PM – 02:00 PM  Session 1 - Plenary Lecture

Session Chair: Thomas Martin, MD

01:30 PM – 01:50 PM  Plenary Lecture - Next Generation CAR T-Cell Therapeutics - Julia Carnevale, MD

01:50 PM – 02:00 PM  Q & A

02:00 PM – 03:30 PM  Session 2 - Non-Hodgkin's Lymphoma

Session Chair: Alexey Danilov, MD, PhD 

02:00 PM – 02:15 PM  Have BTK Inhibitors Replaced Transplant in MCL? - Alexey Danilov, MD, PhD 

02:15 PM – 02:30 PM  DLBCL: Is There Still a Role for Autologous Transplant? - Javier Munoz, MD, MBA

02:30 PM – 02:45 PM  T-Cell Lymphoma – Promises of the Future - Bradley Haverkos, MD

Debate: CAR-T versus Bispecifics in FL

    02:45 PM – 02:55 PM  CAR-T - Naseem Shams Esteghamat, MD, MS

    02:55 PM – 03:05 PM  Bispecifics - Swetha Kambhampati Thiruvengadam, MD

03:05 PM – 03:30 PM  Case-Based Presentation & Panel Discussion - Annie Xiao, MD

03:30 PM – 04:00 PM  Break & Exhibits

04:00 PM – 05:30 PM  Session 3 - Leukemia

Session Chairs: Vinod Pullarkat, MD, MRCP & Brian Jonas, MD, PhD, FACP

04:00 PM – 04:15 PM  Doublets and Triplets: AML Induction in the Era of Targeted Therapies - Brian Jonas, MD, PhD, FACP

04:15 PM – 04:30 PM  Menin Inhibitors: Next Best Thing Since Venetoclax? - Tibor Kovacsovics, MD

04:30 PM – 04:45 PM  Low Risk MDS: Do New Approved Therapies Change Outcomes? - Brian Ball, MD

04:45 PM – 05:00 PM  Case Presentation - Oleg Krijanovski, MD, PhD

05:00 PM – 05:30 PM  Panel Discussion

05:30 PM – 06:30 PM  Reception, Networking, and Exhibits

 
DAY 2 - Saturday, March 29th, 2025
 

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits 

08:00 AM – 09:30 AM  Session 4 - Myeloma

Session Chair: Jeffrey Wolf, MD & Thomas Martin, MD

08:00 AM – 08:15 AM  SMM – With All the New Data – Is Treatment More or Less Controversial? - Lisa X. Lee, MD

08:15 AM – 08:30 AM  Frontline Therapy for the “Frail” – How Do We Define Frail and Which Drugs to Combine? - Julia Erin Wiedmeier-Nutor, MD, MPH

08:30 AM – 08:45 AM  What is High-Risk MM? New Definition and Treatment? - Thomas Martin, MD

08:45 AM – 09:05 AM  What is Best: Maintenance Therapy or Continuous Therapy for TE and TI MM? - Jeffrey Wolf, MD

09:05 AM – 09:30 AM  Case-Based Discussion - Kwan-Keat Ang, MD 

09:30 AM – 10:00 AM  Break & Exhibits

10:00 AM – 11:30 AM  Session 5 - Leukemia

Session Chair: Vinod Pullarkat, MD, MRCP & Jerald Radich, MD

10:00 AM – 10:15 AM  Incorporating Blinatumomab into Frontline ALL Regimens? - Ryan Cassaday, MD

10:15 AM – 10:30 AM  CML: Which TKI? For How Long? -  Jerald Radich, MD

10:30 AM – 10:45 AM  Can CAR T Cure Adult ALL? - Aaron Logan, MD, PhD, MPhil

Debate: Stem Cell Transplant for Ph + ALL

    10:45 AM – 10:55 AM  Transplant is Outdated - Tamer Othman, MD

    10:55 AM – 11:05 AM  Transplant is Still Standard of Care - Vinod Pullarkat, MD, MRCP

11:05 AM – 11:30 AM  Panel Discussion

11:30 AM – 11:45 AM  Session 6 - Global Oncology 

Improving Access to Hematology and Oncology in LMIC - Binaytara Foundation's Approach - Binay Shah, MD, MHA

11:45 AM – 12:30 PM  Session 7 - Treatment Toxicities: Practical Tips on Management

Session Chairs: Thomas Martin, MD; Vinod Pullarkat, MD, MRCP; & Alexey Danilov, MD, PhD

Panel Discussion: Debbie Zamora, NP; Maria Elena Dela Rosa, NP-c, MSN, RN; Samantha Shenoy, MSN, NP; Stacy Pak, PharmD, BCOP 

12:30 PM – 01:30 PM  Lunch & Exhibits

12:45 PM to 1:30 PM Product Theater Sponsored by Johnson & Johnson in Bayroom

Title: Discover CARVYKTI® for Adult Patients with 2L+ Relapsed, Refractory Multiple Myeloma

Speaker: Karolina Faysman, NP

*This is a non-CME accredited activity*

01:30 PM – 03:00 PM  Session 8 - Myeloma

Session Chair: Murali Janakiram, MD & Thomas Martin, MD

01:30 PM – 01:45 PM  Current Results With CAR T-cell Therapy - Murali Janakiram, MD

01:45 PM – 02:00 PM  Current Results With Bispecific T-cell Engager Antibodies - Darren Pan, MD

02:00 PM - 02:10 PM  Management of Toxicity from CARTs and Bispecifics - Can They Be Treated Outpatient? - Samantha Shenoy, MSN, NP 

02:10 PM - 02:20 PM  Best Therapy for Early Relapse - Thomas Martin, MD

02:20 PM - 02:35 PM  Exciting Agents (non-Immunotherapy) for Triple Class Refractory MM - Jack Khouri, MD

02:35 PM – 03:00 PM  Panel Discussion

03:00 PM – 03:30 PM  Break & Exhibits

03:30 PM – 05:00 PM  Session 9 - CLL/LPL and HL

Session Chair: Alexey Danilov, MD, PhD

03:30 PM – 03:45 PM  DLBCL: Embarrassment of Riches? Post-CAR T Space - John Baird, MD

03:45 PM – 04:00 PM  How I Treat LPL - Geoff Shouse, DO, PhD

04:00 PM – 04:15 PM  Evolution of Therapy in Richter's Syndrome - Benjamin Heyman, MD

Debate: CLL Progressing on BTK Inhibitors

    04:15 PM – 04:25 PM  Stay in Class - Bita Fakhri, MD, MPH

    04:25 PM – 04:35 PM  Switch Class - Mazyar Shadman, MD, MPH

04:35 PM – 05:00 PM  Panel Discussion - Paolo Lopedote, MD

05:00 PM  Adjourn

Sonesta Redondo Beach and Marina
300 North Harbor Drive
Redondo Beach, CA 90277
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Conference Chair(s)

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.

Thomas Martin, MD

has a financial relationship (Grant Or Contract) with sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Grant Or Contract) with Janssen;.

Vinod Pullarkat, MD, MRCP

has a financial relationship (Independent contractor) with jazz;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with rigel;.
has a financial relationship (Independent contractor) with amgen;.
has a financial relationship (Independent contractor) with sobi;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with sanofi;.
Session Chair(s)

Brian Jonas, MD, PhD, FACP

has a financial relationship (Grant Or Contract) with Research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell.;.
has a financial relationship (Other) with Data monitoring committee for Gilead;.
has a financial relationship (Independent contractor) with Consultancy/advisory role for AbbVie, BMS , Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell;.

Jeffery Wolf

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

John Baird, MD FACP

has a financial relationship (Financial Support) with Regeneron Pharmaceuticals;.
has a financial relationship (Financial Support) with Janssen Pharmaceuticals;.
has a financial relationship (Financial Support) with Genentech-Roche;.
has a financial relationship (Professional Services) with Kite-Gilead;.
has a financial relationship (Financial Support) with CARGO Therapeutics;.

Brian Ball, MD, MS

has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with Bristol Myers Squibb;.

Julia Carnevale, MD

has no relevant financial relationships to disclose at this time.

Ryan Cassaday, MD

has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Jazz;.
has a financial relationship (Independent contractor) with Autolus;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Grant Or Contract) with Vanda;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Independent contractor) with Pfizer;.

Maria Elena Dela Rosa

has a financial relationship (Professional Services) with ABBVIE ;.
has a financial relationship (Professional Services) with ASTRAZENECA;.

Naseem Esteghamat, MD, MS

has a financial relationship (Other) with Seagen;.

Bita Fakhri, Bita Fakhri, MD, MPH

has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Loxo/Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Adaptive;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with BMS/Juno;.
has a financial relationship (Professional Services) with Beigene;.
has a financial relationship (Professional Services) with Pharmacyclics;.

Brad Haverkos, MD

has no relevant financial relationships to disclose at this time.

Benjamin Heyman, MD

has a financial relationship (Travel) with Genmab;.
has a financial relationship (Other) with Beigene;.
has a financial relationship (Other) with Aztrazeneca;.
has a financial relationship (Independent contractor) with Regeneron;.

Murali Janakiram, MBBS MS

has a financial relationship (Independent contractor) with JANNSENN;.

Brian Jonas, MD, PhD, FACP

has a financial relationship (Independent contractor) with Consultancy/advisory role for AbbVie, BMS , Gilead, Kura, Rigel, Schrodinger, Syndax, and Treadwell;.
has a financial relationship (Grant Or Contract) with Research funding to institution from AbbVie, Amgen, Aptose, AROG, Biomea, BMS, Celgene, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Jazz, Kymera, Loxo, Pfizer, Pharmacyclics, and Treadwell.;.
has a financial relationship (Other) with Data monitoring committee for Gilead;.

Jack Khouri, MD

has a financial relationship (Professional Services) with Janssen;.

Tibor Kovacsovics, MD

has a financial relationship (Other) with Rigel;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.

Lisa Lee

has no relevant financial relationships to disclose at this time.

Aaron Logan, MD, PhD

has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Actinium;.
has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with Sanofi;.

Javier Munoz, MD MS MBA

has a financial relationship (Professional Services) with Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte;.
has a financial relationship (Other) with Targeted Oncology, OncView, Curio, and Physicians' Education Resource;.
has a financial relationship (Financial Support) with Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene;.
has a financial relationship (Professional Services) with MEI, TG Therapeutics, AstraZeneca, Eli Lilly;.

Tamer Othman

has no relevant financial relationships to disclose at this time.

Stacy Pak, Pharm.D., BCOP

has no relevant financial relationships to disclose at this time.

Darren Pan, MD

has a financial relationship (Professional Services) with Sanofi;.

Jerald Radich, MD

has a financial relationship (Stock Options) with Biofidelity;.
has a financial relationship (Other) with HTG;.

Mazyar Shadman, MD, MPH

has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Janssen ;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Stock Options) with Koi Biotherapeutics;.
has a financial relationship (Professional Services) with Fate therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Vincerx ;.
has a financial relationship (Professional Services) with Eli Lily ;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Kite Pharma ;.
has a financial relationship (Professional Services) with Nurix;.

Samantha Shenoy, NP, MSN

has no relevant financial relationships to disclose at this time.

Geoffrey Shouse, DO, PhD

has a financial relationship (Independent contractor) with Beigene USA;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Kite Pharma;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Beigene USA;.

Swetha Thiruvengadam, MD

has a financial relationship (Independent contractor) with AbbVie;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Independent contractor) with Ipsen;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Genmab/AbbVie;.
has a financial relationship (Independent contractor) with Kite Pharmaceuticals;.
has a financial relationship (Professional Services) with Genentech;.

Julia Wiedmeier-Nutor, MD. MPH

has no relevant financial relationships to disclose at this time.

Jeffery Wolf

has no relevant financial relationships to disclose at this time.

Debbie Zamora, AGACNP-BC, MSN

has no relevant financial relationships to disclose at this time.
Case Presenter(s)

Kwan-Keat Ang, MD

has no relevant financial relationships to disclose at this time.

Oleg Krijanovski, MD PhD

has no relevant financial relationships to disclose at this time.

Paolo Lopedote, MD

has no relevant financial relationships to disclose at this time.

Annie Xiao

has no relevant financial relationships to disclose at this time.

Acknowledgement of Commercial Support

This activity is supported by an independent medical education grant from Novartis Pharmaceuticals

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 ACPE Pharmacy

    The Binaytara Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    The ACPE Universal Activity Number assigned to the activity is 0686-0000-25-006-L01-P

    Participants must pass the post-test, complete course evaluation, and provide their NABP e-Profile ID number (ePID) and Date of Birth (MMDD) to Binaytara Foundation within 30-days of participating in the activity. Participants who do not complete these requirements within 30-days of participating in the Live activity will not be awarded the CEUs.

    The Binaytara foundation may distribute a participation certificate containing information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor®.

    After CPE units are processed by ACPE and NABP, pharmacists and pharmacy technicians will be able to login to a comprehensive electronic profile to access information about their completed CPE and Certificate Programs.

    ACPE Pharmacy
  • 10.50 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.